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T-cell regulatory mechanisms in specific immunotherapy
Abstract
Allergen-specific immunotherapy (SIT) is the only treatment which leads to a lifelong tolerance against
previously disease-causing allergens due to restoration of normal immunity against allergens. The
description of T-regulatory (Treg) cells being involved in prevention of sensitization to allergens has led
to great interest whether they represent a major target for allergen-SIT and whether it would be possible
to manipulate Treg cells to increase its efficacy. Activationinduced cell death, anergy and/or immune
response modulation by Treg cells are essential mechanisms of peripheral T-cell tolerance. There is
growing evidence that anergy, tolerance and active suppression are not entirely distinct, but rather
represent linked mechanisms possibly involving the same cells and multiple suppressor mechanisms.
Skewing of allergen-specific effector T cells to Treg cells appears as a crucial event in the control of
healthy immune response to allergens and successful allergen-SIT. The Treg cell response is
characterized by abolished allergen- induced specific T-cell proliferation and suppressed Thelper (Th)1-
and Th2-type cytokine secretion. In addition, mediators of allergic inflammation that trigger
cAMP-associated G-protein-coupled receptors, such as histamine receptor-2, may contribute to
peripheral tolerance mechanisms. The increased levels of interleukin-10 and transforming growth
factor-Bgr that are produced by Treg cells potently suppress IgE production, while simultaneously
increasing production of non-inflammatory isotypes IgG4 and IgA, respectively. In addition, Treg cells
directly or indirectly suppress effector cells of allergic inflammation such as mast cells, basophils and
eosinophils. In conclusion, peripheral tolerance to allergens is controlled by multiple active suppression
mechanisms. It is associated with regulation of antibody isotypes and effector cells to the direction of a
healthy immune response. By the application of the recent knowledge in Treg-dependent mechanisms of
peripheral tolerance, more rational and safer approaches are awaited for the future prevention and cure
of allergen hypersensitivity.
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Allergen-specific immunotherapy (SIT) is the only treat-
ment which leads to a lifelong tolerance against previously
disease-causing allergens due to restoration of normal
immunity against allergens. The description of T-regulatory
(Treg) cells being involved in prevention of sensitization to
allergens has led to great interest whether they represent a
major target for allergen-SIT and whether it would be possi-
ble to manipulate Treg cells to increase its efficacy. Activation-
induced cell death, anergy and/or immune response
modulation by Treg cells are essential mechanisms of
peripheral T-cell tolerance. There is growing evidence that
anergy, tolerance and active suppression are not entirely
distinct, but rather represent linked mechanisms possibly
involving the same cells and multiple suppressor mecha-
nisms. Skewing of allergen-specific effector T cells to Treg
cells appears as a crucial event in the control of healthy
immune response to allergens and successful allergen-SIT.
The Treg cell response is characterized by abolished aller-
gen-induced specific T-cell proliferation and suppressed T-
helper (Th)1- and Th2-type cytokine secretion. In addition,
mediators of allergic inflammation that trigger cAMP-asso-
ciated G-protein-coupled receptors, such as histamine
receptor-2, may contribute to peripheral tolerance mecha-
nisms. The increased levels of interleukin-10 and transform-
ing growth factor- that are produced by Treg cells potently
suppress IgE production, while simultaneously increasing
production of non-inflammatory isotypes IgG4 and IgA,
respectively. In addition, Treg cells directly or indirectly sup-
press effector cells of allergic inflammation such as mast
cells, basophils and eosinophils. In conclusion, peripheral
tolerance to allergens is controlled by multiple active
suppression mechanisms. It is associated with regulation of
antibody isotypes and effector cells to the direction of a
healthy immune response. By the application of the recent
knowledge in Treg-dependent mechanisms of peripheral
tolerance, more rational and safer approaches are awaited
for the future prevention and cure of allergen hypersensitivity.
Copyright © 2008 S. Karger AG, Basel
Although it is well documented that allergen-spe-
cific immunotherapy (SIT) represents the only
approach to achieve tolerance to causative aller-
gens, its mechanism was unclear for a long time.
SIT has been demonstrated to influence the devi-
ated immune response in allergic individuals in a
specific manner and eventually redirect the imm-
une system towards normal immunity. A rise in
allergen-blocking IgG antibodies, particularly of
the IgG4 class [1], the generation of IgE-modulat-
ing CD8 T cells and a decrease in release of
mediators [2–5], was shown to be associated with
successful SIT. Later on, SIT was found to be asso-
ciated with a decrease in interleukin (IL)-4 and IL-
5 production by CD4 Th2 cells, and a shift
towards increased IFN- production by Th1 cells
[6–14]. Distinct Th1 and Th2 subpopulations of T
cells counterregulate each other and play a role in
distinct diseases [6, 7]. The mechanism of repolar-
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ization of specific T-cell activity from dominating
Th2-type towards Th1-type as observed during VIT
was a matter of controversy. A new light was shed
when a further subtype of T cells, with immuno-
suppressive function and cytokine profiles distinct
from either Th1 and Th2 cells, termed regulatory/
suppressor T cells (Treg), was described [8–10]. T-
cell tolerance is characterized by functionally inac-
tivation of the cell to antigen encounter, which
remains alive for an extended period of time in an
unresponsive state. In recognition of the impor-
tance of the phenomenon of immunological toler-
ance, the Nobel Prize in Physiology and Medicine
was awarded in 1960 to Medawar [11] for discov-
ering that skin allografts in mice and chicken can
be accepted if they had been preinoculated during
embryonic development with allogeneic lymphoid
cells, and to Burnet [12, 13] for first proposing that
exposure to antigens before the development of
immune response, specifically abrogates the
capacity to respond to that antigen in later life.
During the last decade, this area of immunology
research had become so popular and promiscuous.
The overall evaluation of the studies on T-cell
unresponsiveness suggests that anergy, tolerance
and active suppression are not entirely distinct, but
rather represent linked mechanisms possibly
involving the same molecular events. The term
anergy was first coined by Von Pirquet [14] in
1908 to describe the loss of delayed-type hypersen-
sitivity to tuberculin in individuals infected with
measles virus. The term was clinically accepted
since then to describe negative tuberculin skin test
results in conditions where it is expected to be
positive. In 1980, the term ‘anergy’ was used to
describe the specific inactivation of B cells in mice
by high doses of antigen [15]. It was subsequently
used for T cells to describe a phenomenon in
which antigen presentation to T-cell clones in the
absence of professional antigen-presenting cells
induced a hyporesponsive state affecting subse-
quent IL-2 production and proliferation upon res-
timulation [16]. A variety of reversible functional
limitations characterize the anergic state, including
cell division, cell differentiation, and cytokine pro-
duction [17, 18]. It is important to note here that in
earlier studies, which are referred to as a basis for
the definition of anergy/tolerance, functional
unresponsiveness was analyzed by non-sophisti-
cated assays such as antigen-induced [3H]thymi-
dine incorporation, IL-2 and total IgG production.
In addition, antigens used in mouse models until
the last few years contained high amounts of
impurities, such as lipopolysaccharide and other
innate immune response-stimulating substances,
which may influence the outcome of the experi-
ments. Although some of the biochemical steps
overlap with anergy, activation-induced cell death
induced by trigger of the death receptors and cas-
pase activation represents a distinct physiological
response [19, 20].
It is still not understood why exposure to aller-
gens causes atopic disorders in some individuals,
but not others, however, it is clear that strong
interaction of environmental and genetic factors
is involved. Four cardinal events during allergic
inflammati n can be classified as activation of
memory/effector T cells and other effector cells
such as mast cells, eosinophils and basophils, their
organ-selective homing, prolonged survival and
reactivation inside the allergic organs and effector
functions [21]. T cells are activated by aeroaller-
gens, food antigens, autoantigens and bacterial
superantigens in allergic inflammation [22, 23].
They are under the influence of skin, lung or
nose-related chemokine network and they show
organ-selective homing [24–26]. A prolonged
survival of the inflammatory cells and strong
interaction with resident cells of the allergic organ
and consequent reactivation is observed in the
subepithelial tissues [27, 28]. T cells play impor-
tant effector roles in atopic dermatitis and asthma
with induction of hyper-IgE, eosinophil survival
and mucus hyperproduction [22, 28, 29] (fig. 1).
In addition, activated T cells induce bronchial
epithelial cell and keratinocyte apoptosis as major
tissue injury events [30–33]. Peripheral T-cell tol-
erance to allergens can overcome all of the above
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pathological events in allergic inflammation, because
they all require T-cell activation.
The initial event responsible for the deve-
lopment of allergic diseases is the generation of
allergen-specific CD4 T-helper (Th) cells. The
current view is that under the influence of IL-4,
naive T cells activated by antigen-presenting cells
differentiate into Th2 cells [34–36]. Once generated,
effector Th2 cells produce IL-4, IL-5 and IL-13, and
mediate several regulatory and effector functions.
These cytokines induce the production of allergen-
specific IgE by B cells, development and recruit-
ment of eosinophils, production of mucus and
contraction of smooth muscles [34, 35, 37].
Furthermore, the degranulation of basophils and
mast cells by IgE-mediated cross-linking of recep-
tors is the key event in type 1 hypersensitivity,
which may lead to chronic allergic inflammation.
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Fig. 1. Peripheral tolerance mechanisms in allergen-SIT and healthy immune response. Immune
deviation towards Treg cell response is an essential step in allergen-SIT and natural allergen expo-
sure of non-allergic individuals. Treg cells utilize multiple suppressor factors, which influence the
final outcome of allergen-SIT. In addition, IL-10 and TGF- induce IgG4 and IgA respectively from B
cells as non-inflammatory Ig isotypes and suppress IgE production. These two cytokines directly or
indirectly suppress effector cells of allergic inflammation such as mast cells, basophils and
eosinophils. In addition, Th2 cells, which are dominated by Treg cells, can no longer induce IgE by
IL-4 and IL-13, and cannot provide cytokines such as IL-3, IL-4, IL-5 and IL-9, which are required for
the differentiation, survival and activity of mast cells, basophils and eosinophils, and mucus-
producing cells. Furthermore, the suppressed Th0/Th1 compartment of allergic inflammation cannot
mediate essential tissue injury mechanisms via IFN-, TNF- and Fas-ligand (L) such as apoptosis of
skin keratinocytes and bronchial epithelial cells (red line: suppression; black line: stimulation).
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Importantly, although Th2 cells are responsible for
the development of allergic diseases, Th1 cells may
contribute to chronicity and effector phase in aller-
gic diseases [30–33, 38, 39]. Distinct Th1 and Th2 2
subpopulations of T cells counterregulate each
other and play a role in distinct diseases [34, 35]. In
addition, recent studies have demonstrated that
peripheral T-cell tolerance is crucial for a healthy
immune response and successful treatment of aller-
gic disorders [40–42]. A further subtype of T cells,
with immunosuppressive function and cytokine
profiles distinct from either Th1 and Th2 cells, ter-
med regulatory/suppressor T cells (Treg), has been
existence in humans has been demonstrated [41,
45, 46]. In addition to Th1 cells, Treg cells are able
to inhibit the development of allergic Th2 responses
[47] and play a major role in allergen-SIT [41, 42].
This review will examine allergen-specific periph-
eral tolerance mechanisms in humans and discuss
novel ways of T-cell suppression.
Peripheral T-Cell Tolerance in Allergen-Specific
Immunotherapy
The symptoms of IgE-mediated allergic reactions –
such as rhinitis, conjunctivitis and asthma – can
be ameliorated by temporary suppression of
HR2 is dominant on Th2 cell
suppresses IL-4, IL-13 and proliferation,
augments suppressive effect of TGF-
HR2
Histamine
IL
-1
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Histamine
IL
-1
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Fig. 2. Regulatory/suppressor functions of histamine by HR2. In maturing DCs, histamine
enhances intracellular cAMP levels and stimulates IL-10 secretion, but suppresses IL-12 by HR2. IL-
10 affects the maturation of DCs to IL-10-producing DCs and induces of IL-10-producing T cells. Th2
cells show increased expression of HR2 and T-cell proliferation and IL-4 and IL-13 production are
negatively regulated by HR2. IL-10 suppresses the antigen-presentation capacity and proinflam-
matory cytokine synthesis of DCs. In addition, Th2 cells are more efficiently suppressed by TGF- in
the presence of histamine via HR2 (red line: suppression; black line: differentiation).
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mediators and immune cells (by antihistamines,
antileukotrienes, 2-adrenergic receptor antago-
nists and corticosteroids) [48–51]. However, a
more long-term solution is allergen-SIT that
specifically restores a normal immunity against
allergens. Allergen-SIT is most efficiently used in
allergy to insect venoms and allergic rhinitis
[52–56]. Despite its usage in clinical practice for
nearly a century, the underlying immunological
mechanisms of allergen-SIT are slowly being
elucidated [40, 42, 57–61]. A rise in allergen-
blocking IgG antibodies, particularly of the IgG4
class, which supposedly block allergen and IgE
facilitated antigen presentation [62–64], the gen-
eration of IgE-modulating CD8 T cells [65] and
a reduction in the numbers of mast cells and
eosinophils, including the release of mediators
[66–68], were shown to be associated with suc-
cessful allergen-SIT. Furthermore, allergen-SIT
was found to be associated with a decrease in IL-
4 and IL-5 production by CD4 T cells [56, 69,
70]. Also a shift from Th2 cytokine pattern
towards increased IFN- production in allergen-
SIT of allergy to bee venom, wasp venom, grass
pollen and house dust mite was observed [69, 71].
It appears however that the induction of a toler-
ant state in peripheral T cells represents an essen-
tial step in allergen-SIT (fig. 1) [40–42, 57].
Peripheral T-cell tolerance is characterized
mainly by suppressed proliferative and cytokine
responses against the major allergens and its T-
cell recognition sites [57]. T-cell tolerance is initi-
ated by autocrine action of IL-10, which is
increasingly produced by the antigen-specific T
cells [40, 41]. Tolerized T cells can be reactivated
to produce either distinct Th1 or Th2 cytokine
patterns depending on the cytokine present in the
tissue microenvironment, and thus directing
allergen-SIT towards successful or unsuccessful
treatment [57].
Peptide immunotherapy (PIT) is another
attractive approach for investigation of peripheral
T-cell tolerance in humans. Short allergen pep-
tides, either native sequences or altered peptide
ligands, with amino acid substitutions do not con-
tain epitopes for IgE cross-linking to induce ana-
phylaxis. There is considerable rationale for
targeting T cells with synthetic peptides based on
such T-cell epitopes. To date, clinical trials of PIT
have been performed in two allergies [72–76].
Relatively long peptides of 27 and 35 amino acids
of the major cat allergen Fel d 1 containing the T-
cell epitopes or mixture of peptides spanning the
whole protein sequence were used to treat allergy
to cats and resulted in the induction of tolerance
in IL-4-producing cells [73, 76]. In the other trial,
PIT of bee venom allergy was performed with a
mixture of short peptides that directly represent
the T-cell epitopes [17, 12, 11], amino acids of the
bee venom major allergen, phospholipase A2 [72].
The study showed modulation of the immune
response against the whole allergen, inducing spe-
cific T-cell tolerance and a decrease in the specific
IgE:IgG4 ratio [72]. Single amino acid alteration
in T-cell epitopes can modify specific T-cell acti-
vation and cytokine production [77]. Rodent
studies suggest that, under highly controlled
experimental conditions, allergic diseases can be
inhibited by altered peptide ligand administra-
tion. Whether this is due to Th2 to Th1 immune
deviation or the induction of Treg cells remains to
be elucidated [77, 78]. Although PIT is theoreti-
cally attractive as a means to avoid IgE-mediated
early phase reactions, it is important to note that
serum IgE in allergic individuals may sometimes
bind to relatively short linear epitopes of protein
allergens [79]. A potential barrier to PIT of allergy
is the apparent complexity of the allergen-specific
T-cell response in terms of epitope usage and
dominant epitopes in humans [80–82].
Peripheral T-Cell Tolerance to Allergens Is
Associated with Regulation of Antibody
Isotypes and Suppression of Effector Cells
The serum levels of specific IgE and IgG4 anti-
bodies delineate allergic and normal immunity to
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allergen. Although peripheral tolerance was
demonstrated in specific T cells, the capacity of B
cells to produce specific IgE and IgG4 antibodies
was not abolished during SIT [57]. In fact, spe-
cific serum levels of both isotypes increased dur-
ing the early phase of treatment. However, the
increase in antigen-specific IgG4 was more pro-
nounced and the ratio of specific IgE to IgG4
decreased by 10- to 100-fold. Also the in vitro
production of PLA-specific IgE and IgG4 anti-
bodies by PBMC changed in parallel to the serum
levels of specific isotypes. A similar change in
specific isotype ratio was observed in SIT of vari-
ous allergies. Moreover, IL-10, which is induced
and increasingly secreted by SIT, appears to
counterregulate antigen-specific IgE and IgG4
antibody synthesis [41]. IL-10 is a potent sup-
pressor of both total and allergen-specific IgE,
while it simultaneously increases IgG4 produc-
tion [41, 83]. Thus, IL-10 not only generates tol-
erance in T cells, but it also regulates specific
isotype formation and skews the specific
response from an IgE- to an IgG4-dominated
phenotype (fig. 1). The healthy immune response
to Der p 1 demonstrated increased specific IgA
and IgG4, small amounts of IgG1 and almost
undetectable IgE antibodies in serum [42]. House
dust mite-SIT did not significantly change spe-
cific IgE levels after 70 days of treatment, how-
ever a significant increase in specific IgA, IgG1
and IgG4 was observed [42]. The increase of spe-
cific IgA and IgG4 in serum coincides with
increased transforming growth factor- (TGF-)
and IL-10 respectively. This may account for the
role of IgA and TGF- as well as IgG4 and IL-10
in peripheral mucosal immune responses to aller-
gens in healthy individuals [41, 84].
Despite the fact that a definite decrease in IgE
antibody levels and IgE-mediated skin sensitivity
normally requires several years of SIT, most
patients are protected against bee stings already
at an early stage of bee venom-SIT. The reason for
this is that effector cells of allergic inflammation,
such as mast cells, basophils and eosinophils,
require T-cell cytokines for priming, survival and
activity, [85, 86] which are not efficiently pro-
vided by suppressed Th2 cells and Treg cells (fig.
1). SIT efficiently modulates the thresholds for
mast cell and basophil activation and decreases
immunoglobulin E-mediated histamine release
[87, 88]. In addition, IL-10 was shown to reduce
proinflammatory cytokine release from mast cells
[89]. Furthermore, IL-10 downregulates eosino-
phil function and activity, and suppresses IL-5
production by human resting Th0 and Th2 cells
[90]. Moreover, IL-10 inhibits endogenous GM-
CSF production and CD40 expression by acti-
vated eosinophils and enhances eosinophil cell
death [91].
T-Regulatory Cells
T cells that were able to suppress immune
responses were described first in the early 1970s
[92]. Suppressor T cells were thought to be a spe-
cialized subpopulation, the effects of which were
mediated in an antigen-specific fashion [65, 93].
Unfortunately, the failure to clearly identify the
mechanisms underlying immune suppression led
to a collapse in the entire field in the 1980s [94].
The concept of T-cell-mediated immune suppres-
sion was started to be strongly explored the mid-
1990s. Many types of suppressor T cells have been
described in a number of systems, and their biol-
ogy has been the subject of intensive investiga-
tion. Although many aspects of the mechanisms
by which suppressor cells exert their effects
remain to be elucidated, it is well established that
Treg cells suppress immune responses via cell-to-
cell interactions and/or the production of sup-
pressor cytokines [40, 41, 44, 95].
Tr1 Cells
Type-1 T-regulatory (Tr1) cells are defined by
their ability to produce high levels of IL-10 and
TGF- [44, 95]. Tr1 cells specific for a variety of
antigens arise in vivo, but may also differentiate
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from naive CD4 T cells. Tr1 cells have a low
proliferative capacity which can be overcome by
IL-15 [96]. Tr1 cells suppress naive and memory
Th1 or Th2 responses via production of IL-10
and TGF- [95]. The use of Tr1 cells to identify
novel targets for the development of new thera-
peutic agents, and as a cellular therapy to modulate
peripheral tolerance in allergy and autoimmu-
nity, can be foreseen [40, 72, 97].
The generation in vitro of a Treg cell subset by
stimulating naive CD4 T cells in the presence of
IL-10, IFN- or a combination of IL-4 and IL-10,
has previously been reported [44, 95]. To over-
come the problems in cytokine profiles of regula-
tory T cells, it has been demonstrated that a
combination of vitamin D3 and dexamethasone
induced human and mouse naive CD4 T cells
to differentiate in vitro into regulatory T cells
[98]. In contrast to the previously described in
vitro derived CD4 T cells, these cells produced
only IL-10, but no IL-5 and IFN-, and further-
more retained a strong proliferative capacity and
prevented central nervous system inflammation
in an IL-10-dependent manner. There is now clear
evidence that IL-10- and/or TGF--producing
Tr1 cells are in vivo generated in humans during
the early course of allergen-SIT, suggesting that
high and increasing doses of allergens induce Tr1
cells in humans [41, 42, 99].
Th3 Cells
Regulatory/suppressor T-cell clones have been
induced by oral feeding of low doses of antigen in
a TCR-transgenic experimental encephalitis
model [8, 100]. CD4 T-cell clones isolated from
mesenteric lymph nodes in orally tolerated ani-
mals produced high levels of TGF-, and variable
amounts of IL-4 and IL-10 upon activation with
appropriate antigen or anti-CD3 antibody [8].
These cells functioned in vivo to suppress
encephalitis induction with myelin basic protein
and were designated as Th3 cells. TGF- and IL-
10 seemed critical, as treatment with neutralizing
antibodies abrogated the disease-protective effects
of these cells. These Treg cells also exerted bystander
immune suppression in vitro.
CD4CD25 Treg Cells
There is clear evidence from various animal
models and human studies for an active mecha-
nism of immune suppression, whereby a distinct
subset of T cells inhibits the activation of conven-
tional T cells in the periphery [101–104]. This
Treg cell population has been determined as
CD4CD25 T cells. The CD4CD25 T cells
constitute 5–10% of peripheral CD4 T cells and
express the IL-2 receptor -chain (CD25) [101].
They can prevent the development of autoimmu-
nity indicating that the normal immune system
contains a population of professional Treg cells.
Elimination of CD4CD25 T cells leads to
spontaneous development of various autoimmune
diseases, such as gastritis or thyroiditis in geneti-
cally-susceptible hosts. In mice these cells have
been shown to express CD45RBlow [43]. The
CD38–CD25CD4 CD45RBlow subpopulation
contains T cells which respond to recall antigens
and produced high levels of cytokines in response
to polyclonal stimulation. In contrast, the
CD38&PLUS; cells within this subpopulation fail
to proliferate or to produce detectable levels of
cytokines, and furthermore inhibit anti-CD3-
induced proliferation induced by CD38– popula-
tion [105].
There are two major hypotheses concerning
the generation of CD4CD25 Treg cells. One
of these suggests that Treg cells emerge from the
thymus as a distinct subset of mature T cells with
defined functions [101, 103]. On the other hand,
several studies have shown that Treg cells may
differentiate from naive T cells in the periphery
upon encountering antigens present at high con-
centrations [44, 98, 106]. It can be proposed that
thymic differentiation accounts for Treg cells that
are specific for self peptides and are devoted to
the control of autoimmune responses, whereas
peripheral differentiation may be required
for environmental antigen-specific T cells for
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which an undesired immune response results in
pathology.
Other T-Regulatory Cells
It has been proposed that, in addition to CD4 T
cells, CD8 Treg cells may have a role in oral tol-
erance [107, 108]. Recent efforts to generate sup-
pressor cell lines in vitro resulted in a population
of CD8CD28– T cells restricted by allogeneic
HLA class I antigens which were able to prevent
upregulation of B7 molecules induced by Th cells
on antigen-presenting cells [109]. This resulted in
the suppression of CD4 T cells in an HLA-non-
restricted fashion [109]. Interestingly, the magni-
tude of a CD8 T-cell-mediated immune response
to an acute viral infection is also subject to con-
trol by CD4CD25 Treg cells. If natural Treg
were depleted with specific anti-CD25 antibody
before infection with virus, the resultant CD8
T-cell response was significantly enhanced sug-
gesting that controlling suppressor effects at the
time of vaccination could result in more effective
immunity [110].
Double negative (CD4–CD8–) TCR-
Treg cells that mediate tolerance in several
experimental autoimmune diseases have been
described [111]. These double negative T cells are
specific for MHC class I molecules and the sup-
pressive effect of these cells on the proliferation
and cytotoxic activity of CD8 T cells with the
same antigen specificity was not mediated by
cytokines, but instead was attributed to Fas-
mediated apoptosis of alloreactive T cells [112].
 T cells with regulatory functions have also
been described. A population of  Treg cells with
a cytokine profile reminiscent of Tr1 cell clones
has been isolated from tumor-infiltrating lym-
phocytes [113]. These Treg cells could play a role
in the inhibition of immune responses to tumors
[114]. It has also been shown that aerosol delivery
of protein antigens resulted in the differentiation
of  T cells with regulatory functions [113]. It
has been observed that induction of tolerance by
various doses of ovalbumin (OVA) was abrogated
in mice lacking TCR- [115]. In contrast, TCR-
-deficient mice have the same degree of IgE-
specific unresponsiveness after aerosol priming
and immunization with OVA [116].
B-Regulatory Cells
A regulatory role for IL-10-secreting B cells has
been recently proposed [117]. These B cells pre-
vented the development of arthritis and their sup-
pressive effect was particularly IL-10-dependent,
because the B cells isolated from IL-10-deficient
mice failed to protect from arthritis.
Dendritic-Regulating Cells
It is generally thought that immature dendritic
cells (DCs) do not appropriately activate T cells,
which may lead to tolerance [118]. In normal
immunity, DCs should not have any restriction
in antigen presentation and they should appro-
priately receive maturation signals given by the
surroundings of the antigen, T cells and other
tissue cells, such as costimulatory ligands,
cytokines, innate immune response-stimulating
(i.e. toll-like receptor triggering) substances.
However, there are some indications that DCs
can induce peripheral T-cell tolerance and a reg-
ulatory DC subset may exist. Pulmonary DCs
fr m mice exposed to respiratory antigen tran-
siently produce IL-10 [119]. These phenotypi-
cally mature pulmonary DCs, which were B7hi,
stimulated the development of CD4 Tr1-like
cells that also produced high amounts of IL-10.
Adoptive transfer of pulmonary DCs from 
IL-10/, but not IL-10–/–, mice exposed to
respiratory antigen induced antigen-specific
unresponsiveness in recipient mice. In accor-
dance with these findings, IL-10 inhibited the
development of fully mature DCs, which
induced a state of alloantigen-specific anergy
in CD4 T cells [120]. These studies show that
IL-10 production by DCs is critical for the
induction of tolerance, and that phenotypically
mature regulatory DCs may exist under certain
circumstances.
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Other Cells with a Possible Regulatory Function
It has been clearly demonstrated that natural killer
cells, epithelial cells, macrophages, glial cells, etc.,
express suppressor cytokines such as IL-10 and
TGF-. Although their role has not been coined
as professional regulatory cells, these cells may
efficiently contribute to the generation and main-
tenance of a regulatory/suppressor type immune
response [121–126]. The expression of suppres-
sor cytokines in resident tissue cells may addi-
tionally contribute to this process (table 1).
Suppression Mechanisms of T-Regulatory Cells
A great deal of uncertainty remains about mecha-
nisms of action of Treg cells. Initial studies have
shown that Treg cells act as suppressor T cells,
which downregulate effector cells and inflamma-
tion models in chronic infection, organ trans-
plantation and autoimmunity [8, 44, 127]. Most
studies have failed to find a soluble factor as a
suppressive mechanism of CD4CD25 Treg
cells. Antigen-induced proliferation of CD4 T
cells was dramatically reduced following cocul-
ture with activated Treg clones, which had been
separated from the responding T cells by a
Transwell insert [128]. However, in Transwell
membrane cultures that separate suppressor cells
and target cells, the distance between two popula-
tions is approximately 2 mm and this may influ-
ence the concentration of suppressor cytokines.
Accordingly, it cannot be possible to rule out an
effect of a cytokine that acts in short distances or
Table 1. Regulatory/suppressor cells and their subsets
Regulatory/suppressor cells Suppressor References
mechanism1
T cells Tr1 IL-10, TGF- 30–35, 102–106
Th3 TGF- 33, 107
CD4CD25 Treg IL-10, TGF-, CTLA-4, 108–113
PD-1, GITR 
CD8CD25CD28–Treg same as CD4CD25 114–117
CD4–CD8– Treg induction of apoptosis 118–119
TCR- Treg IL-10, TGF- 120–123
B-cell subset B-regulatory IL-10 124
DCs DC-regulatory IL-10 125–127
NK cell subset2 NK-regulatory IL-10 131, 132
Macrophages IL-10, TGF- 131
Resident tissue cells2 IL-10, TGF- 128–133
1Suppressor mechanisms are not conclusive. It is possible that multiple other suppressive mecha-
nisms exist.
2NK cells and resident tissue cells are included in the table because of expression of suppressive
cytokines by these cells.
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a membrane-bound cytokine. Indeed, membrane-
bound TGF- might be one of the mechanisms of
suppression of CD4CD25 Treg cells [129]. In
contrast to CD4CD25 Treg cells, suppressive
effects of Tr1 cells were reversed by addition of
neutralizing monoclonal antibody, directed against
TGF- and IL-10, implicating the role of suppres-
sive cytokines in the mechanism of immune sup-
pression both in vitro and in vivo in different
settings and different autoimmune as well as
allergy models [42, 44, 129–131]. This suppression
was a hallmark of Tr1 clones, as OVA-specific
Th1 or Th2 clones, derived from the same mice,
had no suppressive effects, but rather enha-
nced OVA-induced proliferation of naive CD4
T cells [47].
One group of CD4CD25 Treg cells origi-
nate from the thymus as a distinctive subset [101,
103, 132]. Thymectomy at a very early stage of
animal development induces various autoim-
mune diseases in genetically-susceptible animals
[133, 134]. Furthermore, induction of autoim-
mune diseases in an immunodeficient animal
model was prevented by adoptively transferred
CD4 T cells or CD4CD8– thymocytes iso-
lated from normal syngeneic animals. In a rat
model, CD4 Treg cells were found to be of the
CD45RClow phenotype and to produce IL-2 and
IL-4, but not IFN-, upon in vitro stimulation
[133]. IL-4 and TGF- are critical in preventing
autoimmunity, as neutralization of either of these
two cytokines abrogates the protective response.
In another study, CD4CD25 Treg cells from
thymus were shown to exert their suppressive
function via the inhibition of IL-2R -chain in
target T cells, induced by the combined activity of
CTLA-4 and membrane TGF-1 [135].
Studies of this activated CD4 T-cell subpop-
ulation have shown that they do not proliferate
upon normal TCR-mediated stimulation and
suppress proliferation of other T cells. TCR stim-
ulation was required for these cells to exert sup-
pression of other T cells; such suppression,
however, was not confined to T cells specific for
the same antigen. CD4CD25 T cells are the
only lymphocyte subpopulation in both mice and
humans that express CTLA4 constitutively. The
expression apparently correlates with the sup-
pressor function of CTLA4. The addition of anti-
CTLA4 antibody or its Fab (fragment of antigen
binding) reverses suppression in cocultures of
CD4CD25 and CD4CD25– T cells [136].
Similarly, the treatment of mice, which are recipi-
ents of CD4CD45RBlow T cells with these
agents, abrogated the suppression of inflamma-
tory bowel disease [137]. These studies indicate
that signals that result from the engagement of
CTLA4 by its ligands, CD80 or CD86, are
required for the induction of suppressor activity.
Under some circumstances, the engagement of
CTLA4 on the CD4CD25 T cells by antibody
or by CD80/CD86 might lead to inhibition of the
TCR-derived signals that are required for the
induction of suppressor activity.
Programmed death-1 (PD-1) is an immunore-
ceptor tyrosine-based inhibitory motif (ITIM)-
containing receptor expressed upon T-cell
activation. PD-1-deleted mice develop autoim-
mune diseases, suggesting an inhibitory role for
PD-1 in immune responses [138]. Members of
the B7 family, PD-L1 and PD-L2, are ligands for
PD-1. PD-1:PD-L engagement on murine CD4
and CD8 T cells results in inhibition of prolifera-
tion and cytokine production. T cells stimulated
with anti-CD3/PD-L1 display dramatically
decreased proliferation and IL-2 production
[139]. PD-1:PD-L interactions inhibit IL-2 pro-
duction even in the presence of costimulation
and, thus, after prolonged activation, the PD-1:
PD-L inhibitory pathway dominates. Exogenous
IL-2 is able to overcome PD-L1-mediated inhibi-
tion at all times, indicating that cells maintain IL-2
responsiveness.
Glucocorticoid-induced tumor-necrosis fac-
tor receptor family-related gene (TNFRSF18,
GITR) is expressed by CD4CD25 alloanti-
gen-specific and naturally occurring circulating
Treg cells [140, 141]. Stimulation of CD25CD4
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regulatory T cells through GITR breaks immuno-
logical self-tolerance [141]. GITR is upregulated
in CD4CD25– T cells after T-cell receptor
stimulation and it also functions as a survival sig-
nal for activated cells [142]. In addition, CD103
(E7 integrin) and CD122 ( chain of IL-2
receptor) are highly expressed on CD4CD25
Treg cells, which correlates with their suppressive
activity [143, 144].
An X-linked forkhead/winged helix transcrip-
tion factor, FoxP3 (Scurfin) is essential for the
suppressive function of CD4CD25 Treg cells
[145, 146]. It is highly expressed in CD4CD25,
but not CD4CD25– Treg cells [145, 146]. It acts
as a silencer of cytokine gene promoters and
programs the development and function of
CD4CD25 Treg cells [145–148]. Mutations in
the FoxP3 gene in humans leads to a severe
immune dysregulation with polyendocrinopathy,
enteropathy and hyper-IgE known as IPEX syn-
drome [149].
The failure of Treg cells to proliferate after
TCR stimulation in vitro has suggested they are
naturally anergic. However, Treg cells expressing
a transgenic TCR were shown to proliferate and
accumulate locally in response to transgenically
expressed tissue antigen, whereas their CD25–
counterparts are depleted at such sites [150].
CD4CD25 Treg cells population is composed
of two Treg subsets that have distinct phenotypes.
Some Treg remain quiescent and have a long
lifespan, in the order of months, whereas the
other Treg cells (mainly the autoantigen-specific
ones) divide extensively and express multiple
activation markers [151].
Clinical Relevance of T-Regulatory Cells
Since the concept of professional suppressor cells
is recovering interest among the immunological
community, it is now time to consider how the
manipulation of regulatory/suppressor T cells
might be used clinically. As tumor antigens are an
important group of autoantigens, the depletion of
Treg cells should result in an enhanced immune
response to tumor vaccines. Several studies have
shown that the antibody-mediated depletion of
CD25 T cells facilitates the induction of tumor
immunity [152, 153].
Currently, the relationship between the differ-
ent Treg cell populations is unclear with respect
to their development, and activation. However,
numerous animal experiments have clearly shown
that Treg cells can suppress both Th1 and Th2
responses in vivo and thereby actively suppress
the development of autoimmune and allergic
responses. Recent studies reported that the appli-
cation of in vitro engineered allergen-specific
Treg cells lines protected mice from developing
allergen-induced Th2 responses [154].
In humans, there is circumstantial evidence to
suggest that Treg cells play a major role in the
inhibition of allergic disorders. It has been
reported that IL-10 levels in the bronchoalveolar
lavage fluid of asthmatic patients are lower than
in healthy controls, and that T cells from children
suffering from asthma also produce less IL-10
mRNA than T cells from control children [155,
156]. These findings indicate that increased IL-10
production is associated with decreased allergic
reactions. As Treg cells are a major source of IL-
10, it has been speculated that Treg cells secreting
IL-10 are involved in the suppression of allergic
Th2 responses in humans. Several human aller-
gen-SIT studies supported this hypothesis [41,
72, 157]. In contrast, some studies demonstrated
that increased IL-10 levels are not associated with
less allergic disease [158]. IL-10 may also pro-
mote airway hyperresponsiveness [159] and even
eosinophilia [160] in allergy models. In contrast
to its known T-cell-suppressive activity, some
reports imply a role for TGF- in the pathogene-
sis of asthma, particularly in remodeling of
injured lung tissue in humans [161]. A recent
report indicated that the increased allergic
inflammation observed after blocking of CTLA-4
is clearly associated with decreased TGF- levels
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in the bronchoalveolar lavage fluid of these ani-
mals [162]. Furthermore, inhibition of experi-
mental tracheal eosinophilia was also due to the
induction of CD4 T cells secreting TGF-
[163].
An alloantigen-independent, systemic expan-
sion of the maternal CD4CD25 T cells with
dominant regulatory T-cell activity has been
demonstrated [164]. In addition to their function
in suppressing autoimmune responses, maternal
Treg cells suppressed an aggressive allogeneic
response directed against the fetus. Their absence
led to a failure of gestation due to immunological
rejection of the fetus.
To analyze human in vivo existence of Treg
cells, lymphocyte populations in human lymph
nodes with a special emphasis on the CD4
CD25 Treg cells have been investigated [165].
CD4CD25 T cells constitutively coexpressed
high levels of CD152. Similar to Treg cells from
peripheral blood, Treg cells from lymph node
were in vitro anergic and efficiently inhibited
other CD4 and CD8 lymphocyte prolifera-
tion [165]. Treg cells may play destructive roles in
cancer and chronic infectious diseases [166–171].
Further studies are needed to demonstrate in the
clinic, whether in vivo generation or adoptive
transfer of Treg cells and/or their related suppres-
sive cytokines may change the course of allergy
and asthma. Small molecular weight compounds
that may generate Treg cells or increase their sup-
pressive properties is an important target not
only for the use in allergy and asthma, but also
for transplantation and autoimmunity.
cAMP-Stimulating G-Protein-Coupled
Receptors in Peripheral Tolerance
The superfamily of seven-transmembrane G-protein-
coupled receptors is the largest and most diverse
group of membrane-spanning proteins [172].
Within all identified human genes, approximately
1,000 encode G-protein-coupled receptors. Many
established G-protein-coupled receptor systems
have been successfully exploited by the pharma-
ceutical industry to become the target for approx-
imately 40% of the currently available drugs
[172]. As a small molecular weight monoamine
that binds to four different G-protein-coupled
receptors, histamine was recently demonstrated
to regulate several essential events in the immune
response [173, 174]. The expression of these
receptors on different cells and cell subsets is
regulated and, apparently, diverse effects of hista-
mine on immune regulation are due to differen-
tial expression of these receptors and their
distinct intracellular signals. Histamine receptor
(HR)2 is coupled to adenylate cyclase and studies
in different species and several human cells
demonstrated that inhibition of characteristic
features of the cells by primarily cAMP formation
dominates in HR2-dependent effects of hista-
mine [175]. Recent studies indicated that HR3
and HR4 may antagonize with HR2-mediated
suppression of the cells [176–178].
Histamine actively participates in functions
and activity of DC precursors as well as their
immature and mature forms. Immature and
mature DCs express all four HRs [179–182]. In
the differentiation process of type 1 DC from
m nocytes, HR1 and HR3 act as positive stimu-
lants that increase antigen-presentation capacity
and proinflammatory cytokine production and
Th1-priming activity. In contrast, HR2 acts as a
suppressive molecule for antigen-presentation
capacity, enhances IL-10 production and induces
of IL-10-producing T cells [183–185].
In monocytes stimulated with toll-like receptor-
triggering bacterial products, histamine inhibits
the production of proinflammatory IL-1-like
activity, TNF- and IL-12, but enhances IL-10
secretion, through HR2 stimulation [185–187].
Histamine induces intracellular Ca2 flux, actin
polymerization, and chemotaxis in immature
DCs due to stimulation of HR1 and HR3 sub-
types. Maturation of DCs results in loss of these
responses. In maturing DCs, however, histamine
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dose-dependently enhances intracellular cAMP
levels and stimulates IL-10 secretion, while
inhibiting production of IL-12 via HR2 [184].
It has been demonstrated that differential pat-
terns of HR expression on Th1 and Th2 cells
determine reciprocal T-cell responses following
histamine stimulation [49]. Th1 cells show pre-
dominant, but not exclusive expression of HR1,
while Th2 cells show increased expression of
HR2. Histamine enhances Th1-type responses by
triggering the HR1, whereas both Th1- and Th2-
type responses are negatively regulated by HR2,
due to activation of different biochemical intra-
cellular signals [49]. In mice, deletion of HR1
results in suppression of IFN- and dominant
secretion of Th2 cytokines (IL-4 and IL-13).
HR2-deleted mice show upregulation of both
Th1 and Th2 cytokines. In addition, histamine
stimulation induced IL-10 secretion through
HR2 [188]. Increased IL-10 production in both
DCs and T cells may account for an important
regulatory mechanism in the control of inflam-
matory functions through histamine. In accor-
dance with this phenomenon, it has recently been
demonstrated that histamine supports the sup-
pressive effect of TGF- on T cells via HR2 [189].
Th2 cells are more affected by histamine-
enhanced TGF- suppression, which is particularly
important for the regulation of allergen-specific
T cells in allergic immune responses.
Clinical Evidence for T-Regulatory Function of
Histamine Receptors
Considerable evidence has emerged to suggest
that histamine participates in the immune regu-
lation of the inflammatory response in several
diseases. Histamine interferes with the peripheral
tolerance induced during SIT in several path-
ways. Histamine induces the production of IL-10
by DCs [184]. In addition, histamine induces IL-
10 production by Th2 cells [188]. Furthermore,
histamine enhances the suppressive activity of
TGF- on T cells [189]. All three of these effects
are mediated via HR2, which is relatively highly
expressed on Th2 cells and suppresses IL-4 and
IL-13 production and T-cell proliferation [49].
Apparently, these recent findings suggest that
HR2 may represent an essential receptor that par-
ticipates in peripheral tolerance or active sup-
pression of inflammatory/immune responses.
The long-term protection from honeybee
stings by terfenadine premedication during rush
immunotherapy with honeybee venom in a double-
blind, placebo-controlled trial was analyzed [190].
After an average of 3 years, 41 patients were re-
exposed to honeybee stings. Surprisingly, none of
20 patients who had been given HR1 antihista-
mine premedication, but 6 of 21 given placebo,
had a systemic allergic reaction to the re-expo-
sure by either a field sting or a sting challenge.
This highly significant difference suggests that
antihistamine premedication during the initial
dose-increase phase may have enhanced the
long-term efficacy of immunotherapy. Expression
of HR1 on T lymphocytes is strongly reduced
during ultrarush immunotherapy, which may
lead to a dominant expression and function of
tolerance-inducing HR2. This indicates a positive
role of histamine in immune regulation during
SIT [191].
Selective HR2 antagonists have attracted inter-
est because of their potential immune response-
modifying activity [192]. Most data suggest that
cimetidine has a stimulatory effect on the
immune system, possibly by blocking the recep-
tors on subsets of T lymphocytes and inhibiting
HR2-induced immune suppression. Cimetidine
has also been used to restore immune functions
in patients with malignant disorders, HIV/AIDS
and other viral infections [193–195]. Although
their systemic usage may cause side effects such
as ulcer development, together these findings are
tempting to investigate local usage of selective
agonists of HR2 and antagonists of HR3 and
HR4 in the treatment of allergic diseases. App-
arently, due to same signal transduction patterns,
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2-adrenergic receptors may function similar to
HR2 in humans [196, 197]. The role of histamine
and other redundant G-protein-coupled recep-
tors in the regulation of immune/inflammatory
pathways in allergic inflammation remain to be
intensely focused in future studies.
Conclusion
There is growing evidence supporting the role for
Treg cells and/or immunosuppressive cytokine-
IL-10 as a mechanism, by which venom-SIT and
healthy immune response to venoms is mediated
leading to both suppression of Th2 responses,
ensuring a well-balanced immune response and a
switch from IgE to IgG4 antibody production
(fig. 1). Peripheral T-cell tolerance is the key
immunological mechanism in healthy immune
response to self and non-infectious, non-self anti-
gens. This phenomenon is clinically well docu-
mented in allergy, autoimmunity, transplantation,
tumor and infection. There is growing evidence
supporting the role for Treg cells and/or immu-
nosuppressive cytokines as a mechanism, by which
allergen-SIT and healthy immune response to
allergens is mediated (fig. 1). In addition to the
treatment of established allergy, it is essential to
consider prophylactic approaches before initial
sensitization has taken place. Preventive vacci-
nes that induce Treg responses can be developed.
Allergen-specific Treg cells may in turn dampen
both the Th1 and Th2 cells and cytokines,
ensuring a well-balanced immune response.
Enhancement of the number and activity of Treg
cells could be an obvious goal for the suppression
of allograft rejection, graft-versus-host disease
and autoimmunity. Treg cells may not be always
responsible for healthy immune response,
because several studies have shown that they may
be responsible for the chronicity of infections and
tumor tolerance. Treg cell populations have
proven possible, but difficult to grow, expand and
clone in vitro. A crucial area for future studies is
the identification of drugs, cytokines or costimu-
latory molecules that induce the growth while
preserving the suppressor function of the Treg
cells. These mechanisms can be better used by
improvement of current treatment using recom-
binant allergens or peptide therapy. The elabora-
tion of more efficacious desensitization methods
including rapid protocols and antihistamine
pretreatment also hold a promise for further
development.
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